pharma news

News

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

FDA knocks back Biogen's high-dose Spinraza

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

News

Rendering of planned Houston facility, via Eli Lilly

Lilly names Houston as site for $6.5bn API facility

Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.

News

David Hallal, Scholar Rock's chairman and chief executive

Manufacturing issues block FDA nod for Scholar Rock SMA drug

Unresolved issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's SMA drug apitegromab.

Joy as uniQure Huntington's therapy clears pivotal trial

BMS eyes filings for myeloma 'celmod' iberdomide

MSD's $349m alliance with Variational, and other AI news

FDA knocks back Biogen's high-dose Spinraza

Lilly names Houston as site for $6.5bn API facility

Manufacturing issues block FDA nod for Scholar Rock SMA drug

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks